Short-term psychological impacts of Alzheimer's disease risk disclosure based on blood-biomarker results.

INTRODUCTION

Blood-based biomarkers (BBMs) of Alzheimer's disease (AD) provide important information about risk for dementia, but little is known about the psychological impact of sharing BBM results to participants with mild cognitive impairment (MCI). Most AD risk disclosure studies have been conducted in cognitively unimpaired individuals and have not used BBMs. This pilot randomized trial tests the hypothesis that disclosing AD risk based on BBMs is not associated with increased psychological harm compared to standard disclosure methods.

METHODS

Participants (n = 27, 73 ± 11 years) with MCI were enrolled and randomized to the intervention (n = 16) or control (n = 11) arm. Participants received a risk estimate based on their age, sex, and equivalent Mini-Mental State Examination score for both groups, with plasma phosphorylated tau 181 results included for the intervention group. Participants completed questionnaires assessing depression, anxiety, and hopelessness prior to disclosure and 2 weeks later. A repeated measures multivariate analysis of variance (MANOVA) was used to determine changes in psychological responses over the follow-up period with a time x group interaction term assessing group differences.

RESULTS

Participants in the intervention and control group were similar across baseline demographic and clinical factors (P values ≥ 0.23). Repeated measures MANOVA showed a significant reduction in psychological symptoms from baseline to 2-week follow-up (P = 0.006) in the combined sample. Follow-up univariate models showed the reduction was driven by a significant reduction in anxiety (mean ± standard deviation; baseline = 13.3 ± 7.7; follow-up = 9.8 ± 9.9; P = 0.02). Time x group interaction was non-significant (P = 0.31) indicating similar psychological responses across groups.

DISCUSSION: In this pilot study of participants with MCI, psychological response to learning risk of progression to dementia did not differ between those who received a risk estimate based on a BBM versus standard clinical information. Two weeks after disclosure, there was an overall decline in anxiety. These preliminary findings suggest that AD risk disclosure using BBMs is not associated with psychological distress.